SUDEEPPHRM

Sudeep Pharma Limited

Specialty ingredients and battery materials manufacturer

Commodities›Chemicals›Chemicals & Petrochemicals›Specialty Chemicals

sudeepgroup.com

Ask AI

Key metrics

Price as of 2026-10-16

Stock price

₹1000.70

Market cap

11,303 Cr

Stock P/E

61.9

P/B

12.80

ROE (FY26)

19.3%

ROCE (FY26)

22.5%

Operating margin (FY26)

32.2%

Debt / equity (FY26)

0.17

OCF / EBITDA (FY26)

31.3%

OCF / EBITDA (3Y)

31.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Sudeep Pharma makes ingredients for pharmaceutical, food and nutrition manufacturers, grown from a pharma excipients business into specialty ingredients, and sells mainly to export markets across about 100 countries.

Company snapshot

13thBy market cap

Ranked among 68 companies in Specialty Chemicals.

What we see

Positives

✓Net margin of 27.1% — the business keeps a healthy share of every rupee it earns.

Concerns

✗Only 31% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.

3 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

Metric	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	163 Cr	172 Cr	182 Cr	158 Cr
Operating expenses (approx.)	107 Cr	112 Cr	120 Cr	103 Cr
EBITDA	55 Cr	60 Cr	63 Cr	55 Cr
OPM %	34.1%	34.8%	34.3%	34.7%
Other income	10 Cr	7 Cr	6 Cr	5 Cr
Interest	2 Cr	1 Cr	2 Cr	2 Cr
Depreciation	4 Cr	4 Cr	4 Cr	4 Cr
Profit before tax	60 Cr	62 Cr	63 Cr	54 Cr
Tax %	21.4%	22.8%	22.6%	25.2%
Net profit	47 Cr	48 Cr	49 Cr	41 Cr
EPS (₹)	₹4.20	₹4.29	₹4.38	₹3.59

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	429 Cr	459 Cr	502 Cr	642 Cr	Sign in free for the trailing twelve months
Operating expenses (approx.)	340 Cr	278 Cr	312 Cr	420 Cr	Sign in free for the trailing twelve months
EBITDA	89 Cr	182 Cr	190 Cr	222 Cr	Sign in free for the trailing twelve months
OPM %	20.8%	39.6%	37.8%	34.6%	Sign in free for the trailing twelve months
Other income	10 Cr	6 Cr	9 Cr	29 Cr	Sign in free for the trailing twelve months
Interest	5 Cr	4 Cr	6 Cr	8 Cr	Sign in free for the trailing twelve months
Depreciation	8 Cr	9 Cr	11 Cr	15 Cr	Sign in free for the trailing twelve months
Profit before tax	86 Cr	175 Cr	183 Cr	228 Cr	Sign in free for the trailing twelve months
Tax %	27.5%	23.8%	24.1%	23.6%	Sign in free for the trailing twelve months
Net profit	62 Cr	133 Cr	139 Cr	174 Cr	Sign in free for the trailing twelve months
EPS (₹)	₹5.74	₹12.28	₹12.78	₹15.50	Sign in free for the trailing twelve months
Dividend payout %	—	—	—	0.0%	Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	1 Cr	1 Cr	10 Cr	11 Cr
Reserves	222 Cr	355 Cr	483 Cr	872 Cr
Borrowings	82 Cr	75 Cr	135 Cr	148 Cr
Other liabilities	115 Cr	83 Cr	89 Cr	128 Cr
Total liabilities	420 Cr	514 Cr	717 Cr	1,175 Cr
Fixed assets (net)	149 Cr	167 Cr	177 Cr	224 Cr
CWIP	26 Cr	45 Cr	88 Cr	178 Cr
Investments	3 Cr	0.13 Cr	0.14 Cr	0 Cr
Loans & advances	—	—	—	0.29 Cr
Inventories	71 Cr	67 Cr	129 Cr	216 Cr
Trade receivables	94 Cr	145 Cr	185 Cr	228 Cr
Cash & bank	10 Cr	14 Cr	37 Cr	27 Cr
Other assets	67 Cr	77 Cr	101 Cr	302 Cr
Total assets	420 Cr	514 Cr	717 Cr	1,175 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	48 Cr	66 Cr	49 Cr	70 Cr
Cash from investing	-50 Cr	-49 Cr	-79 Cr	-327 Cr
Cash from financing	-10 Cr	-13 Cr	53 Cr	247 Cr
Net cash flow	-11 Cr	4 Cr	23 Cr	-10 Cr
Free cash flow (OCF − Capex)	1 Cr	13 Cr	-15 Cr	-49 Cr

Ratios

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE %	29.7%	41.5%	30.0%	22.5%
ROE %	27.9%	37.4%	28.1%	19.3%
Debtor days	80	115	134	129
Inventory days	129	158	224	292
Days payable	70	120	106	92
Cash conversion cycle	139	153	253	328
OCF / EBITDA %	54.3%	36.2%	25.7%	31.3%
OCF / EBITDA % (3 years)	—	—	35.3%	31.0%
Debt / equity	0.37	0.21	0.27	0.17
Current ratio	1.35	2.01	2.43	3.09
Net debt / EBITDA	0.81	0.34	0.52	0.55